Targeting virulence: can we make evolution-proof drugs?

@article{Allen2014TargetingVC,
  title={Targeting virulence: can we make evolution-proof drugs?},
  author={Richard C. Allen and Roman Popat and Stephen P Diggle and Sam P. Brown},
  journal={Nature Reviews Microbiology},
  year={2014},
  volume={12},
  pages={300-308}
}
Antivirulence drugs are a new type of therapeutic drug that target virulence factors, potentially revitalising the drug-development pipeline with new targets. As antivirulence drugs disarm the pathogen, rather than kill or halt pathogen growth, it has been hypothesized that they will generate much weaker selection for resistance than traditional antibiotics. However, recent studies have shown that mechanisms of resistance to antivirulence drugs exist, seemingly damaging the 'evolution-proof… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 37 times over the past 90 days. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 102 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 105 references

Resistance to the quorumquenching compounds brominated furanone C-30 and 5-fluorouracil in Pseudomonas aeruginosa clinical isolates

  • R García-Contreras
  • Pathog. Dis. 68,
  • 2013

Identification of the binding site of Brucella virB8 interaction inhibitors

  • Smith, A M.
  • Chem. Biol
  • 2012

Similar Papers

Loading similar papers…